MelTec Founder, Walter Schubert of Otto von Guericke University Suspends Licensing of All His Patents to MelTec GmbH Until Completion of Structural Reorganization.

Business Editors/Health/Medical Writers

MAGDEBURG, Germany--(BUSINESS WIRE)--July 16, 2003

New Challenges in ALS, in Cancer and for MELK Platform Technology

Walter Schubert, founder and partner of MelTec GmbH today announced that he has suspended all his patents to MelTec GmbH until MelTec's business structure has been reorganized.

Schubert is the inventor of the patented MELK Robotic Technology, which enables protein networks to be mapped directly in morphologically intact cells and tissues for the first time. Schubert says that scientific work over the last few years has provided important new insights into cell function and has generated significant technological progress in MELK technology and its applications in discovering targets and drugs. Projects such as "Biochance" and "CELLECT" in particular, which the German BMBF has awarded to MelTec, the Otto-von-Guericke University of Magdeburg and other universities in Germany, have strongly contributed to this progress. As far as methodical and conceptual approaches are concerned, progress has been made in deciphering protein networks in human cells and tissues.

"All protein networks together constitute the entire functional plan of a cell," said Schubert. "Given that MELK Robotic technology has been fully developed to a mature stage, it is now time to approach the systematic deciphering of the cellular protein networks in health and disease in humans."

In terms of the application of MELK technology, interesting new products have been found. Indeed, a new therapeutic approach and compounds for Amyotrophic Lateral Sclerosis (ALS) and cancer, derived ...